Prevention of cardiovascular ischemic events: high-risk and secondary prevention.
Genest
Jacques
J
Division of Cardiology, McGill University Health Center, Montreal, QC, Canada H3A 1A1. jacques.genest@muhc.mcgill.ca
Pedersen
Terje R
TR
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D002318:Cardiovascular Diseases / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008074:Lipoproteins / Q000097:blood; D017202:Myocardial Ischemia / Q000209:etiology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012307:Risk Factors; D040242:Risk Reduction Behavior
D000806:Angiotensin-Converting Enzyme Inhibitors; D005343:Fibrinolytic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D002784:Cholesterol